GIP; GLP-1 and glucagon receptor tri-agonist
Retatrutide 1 mg subcutaneous once weekly
RETA_SC_1MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.25 (-10.74 to 2.31) | 0.43 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -5.78 (-11.58 to 4.09) | 0.14 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.99 (0.18 to 4.80) | 0.54 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.19 (0.46 to 3.03) | 0.85 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.95 (0.14 to 5.53) | 0.84 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.73 (0.22 to 2.24) | 0.82 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.80 (0.41 to 8.43) | 0.53 |